148 related articles for article (PubMed ID: 9704934)
1. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia.
Pierce A; Owen-Lynch PJ; Spooncer E; Dexter TM; Whetton AD
Oncogene; 1998 Aug; 17(5):667-72. PubMed ID: 9704934
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
Møller GM; Frost V; Melo JV; Chantry A
FEBS Lett; 2007 Apr; 581(7):1329-34. PubMed ID: 17349636
[TBL] [Abstract][Full Text] [Related]
3. Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha.
Wark G; Heyworth CM; Spooncer E; Czaplewski L; Francis JM; Dexter TM; Whetton AD
Oncogene; 1998 Mar; 16(10):1319-24. PubMed ID: 9546433
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor.
Pierce A; Spooncer E; Ainsworth S; Whetton AD
Oncogene; 2002 May; 21(19):3068-75. PubMed ID: 12082538
[TBL] [Abstract][Full Text] [Related]
5. Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation.
Pierce A; Spooncer E; Wooley S; Dive C; Francis JM; Miyan J; Owen-Lynch PJ; Dexter TM; Whetton AD
Oncogene; 2000 Nov; 19(48):5487-97. PubMed ID: 11114726
[TBL] [Abstract][Full Text] [Related]
6. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
Ramaraj P; Singh H; Niu N; Chu S; Holtz M; Yee JK; Bhatia R
Cancer Res; 2004 Aug; 64(15):5322-31. PubMed ID: 15289338
[TBL] [Abstract][Full Text] [Related]
7. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
[TBL] [Abstract][Full Text] [Related]
8. Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.
Underhill-Day N; Pierce A; Thompson SE; Xenaki D; Whetton AD; Owen-Lynch PJ
Br J Haematol; 2006 Mar; 132(6):774-83. PubMed ID: 16487179
[TBL] [Abstract][Full Text] [Related]
9. c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia.
Wisniewski D; Strife A; Berman E; Clarkson B
Leukemia; 1996 Feb; 10(2):229-37. PubMed ID: 8637231
[TBL] [Abstract][Full Text] [Related]
10. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
11. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells.
Coppo P; Dusanter-Fourt I; Millot G; Nogueira MM; Dugray A; Bonnet ML; Mitjavila-Garcia MT; Le Pesteur D; Guilhot F; Vainchenker W; Sainteny F; Turhan AG
Oncogene; 2003 Jun; 22(26):4102-10. PubMed ID: 12821944
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
[TBL] [Abstract][Full Text] [Related]
13. Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia.
Kabarowski JH; Witte ON
Stem Cells; 2000; 18(6):399-408. PubMed ID: 11072027
[TBL] [Abstract][Full Text] [Related]
14. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
15. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
16. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
Carlesso N; Griffin JD; Druker BJ
Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
[TBL] [Abstract][Full Text] [Related]
17. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
18. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice.
Peters DG; Klucher KM; Perlingeiro RC; Dessain SK; Koh EY; Daley GQ
Oncogene; 2001 May; 20(21):2636-46. PubMed ID: 11420675
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
20. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
